Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Kolon Life Science Inc. (102940.KQ)
Seoul, KR
Kolon Life Science Inc. is primarily engaged in the creation and distribution of pharmaceutical products and environmental materials. The company's operations are organized into two distinct units: Chemical and Bio. Its Chemical division manages both pharmaceutical activities and the development of specialty chemicals. In contrast, the Bio business unit is focused on providing contract development and manufacturing services for biopharmaceuticals. The enterprise was founded on April 21, 2000, and its corporate headquarters are situated in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.03% | -1.27% | -4.06% | -10.82% | +21.84% | +16.99% | +114.60% | +71.34% | +131.49% | -47.76% | +100.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+29.5% ★ Q1'26: +10.8% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+125.6% ★ Q1'26: +88.2% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-11.7% Q1'26: -20.8% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+7.1% Q1'26: +44.4% (vs Q1'25)
-
ROIC Chemicals: +3.4%+2.1% Q1'26: +10.0% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+4.2% Q1'26: +5.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×4.06× Q1'26: 1.13× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
140.60M
est.
|
148.54B
est: 170.30M (+87,123.3%)
|
| EBITDA |
-18.25M
est.
|
-62.42B
est: -22.11M (-282,199.4%)
|
| EBIT |
-28.19M
est.
|
-76.46B
est: -34.15M (-223,802.0%)
|
| Net Income |
—
est.
|
-92.32B
|
| SGA |
12.39M
est.
|
30.45B
est: 15.00M (+202,887.5%)
|
| EPS |
—
est.
|
-8,098.00
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 15.7K | 0.42% |
| 2 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 14.0K | 0.33% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 61.7K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 45.2K | 0.29% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 37.8K | 0.28% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 1.5K | 0.44% |
| 7 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 327.44 | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 102940.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
